E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy subjects - prevention of smallpox infection |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041197 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: The main objective of the trial is to evaluate the immunogenicity of MVA-BN® (IMVAMUNE TM) smallpox vaccine concerning the ELISA specific humoral immune response compared between a group of subjects with history of smallpox vaccination (Group 4: 1 dose MVA-BN®, 1 dose placebo) versus a group without history of smallpox vaccination (Group 1: 2 doses MVA-BN®), i.e. to prove that a single dose schedule would be sufficient to boost the immunity in a previously vaccinated population.
Primary safety objective: To compare the four different vaccination groups with regard to ECG changes and cardiac symptoms.
|
|
E.2.2 | Secondary objectives of the trial |
To compare the ELISA specific immune response of the four different vaccination groups - comparison combinations not done for the primary objective.
To compare the four different vaccination groups with regard to immune response measured with a plaque reduction neutralization test (PRNT).
To assess the kinetics of the immune responses after 1 (Group 2) and 2 (Group 1) doses of MVA-BN® (IMVAMUNE TM) in vaccinia naïve subjects.
To compare the four different vaccination groups with regard to safety and reactogenicity.
To compare the safety of one (Group 2) and two (Group 1) vaccinations with MVA-BN® (IMVAMUNE TM) in vaccinia-naïve subjects with placebo (Group 3) and historical / recently published data of Dryvax® immunization in vaccinia-naive subjects.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
All groups 1. Male and female subjects between 18 and 55 years of age. 2. Women must have a negative serum pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours prior to vaccination. 3. Women of childbearing potential must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the study, and must not become pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal or surgically sterilized. (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products.) 4. Read, signed and dated informed consent document after being advised of the risks and benefits of the study in a language understood by the subject signed, and prior to performance of any study specific procedure. 5. Troponin I within normal institutional limits. 6. White blood cells ≥ 2500/mm3 and ≤ 11,000/ mm3. 7. Absolute neutrophil count (ANC) ≥ 1000/mm3. 8. Negative urine glucose by dipstick or urinalysis. 9. Hemoglobin ≥ LLN. 10. Platelets 100 – 440/nl. 11. Adequate renal function defined as: a. Serum creatinine without clinically significant findings. b. Urine protein ≤ 30 mg/dL or none or trace proteinuria (by urinalysis or dip stick). 12. Adequate hepatic function defined as: a. Total bilirubin ≤ 1.5 x ULN in the absence of other evidence of significant liver disease (healthy subjects without clinical disease with Morbus Meulengracht can be included). b. AST (SGOT), ALT (SGPT) and alkaline phosphatase without clinically significant findings. 13. Electrocardiogram (ECG) without abnormal findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV-node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, 2 premature ventricular contractions (PVC) in a row, ST elevation consistent with ischemia). 14. Availability for follow-up for the planned duration of the study (26 weeks after last vaccination).
Groups 1, 2 and 3 (All vaccinia-naïve subjects) additionally: 1. No history of known or suspected previous smallpox vaccination. 2. No detectable vaccinia scar.
Group 4 (All previously vaccinated subjects) additionally: 1. History of previous smallpox vaccination (documented and/or typical vaccinia scar). 2. Most recent smallpox vaccination ≥ 5 years.
|
|
E.4 | Principal exclusion criteria |
1. Pregnant or breast-feeding women. 2. Uncontrolled serious infection i.e. not responding to antimicrobial therapy. 3. History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject. 4. History of or active autoimmune disease. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded. 5. Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment. 6. History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Subjects with history of skin cancer at the vaccination site are excluded. 7. History or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders. 8. Clinically significant mental disorder not adequately controlled by medical treatment. 9. Any condition which might interfere with study objectives or would limit the subject’s ability to complete the study or to be compliant in the opinion of the investigator. 10. History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, or any other heart condition under the care of a doctor. 11. History of an immediate family member (father, mother, brother, or sister) who died due to ischemic heart disease before age 50 years. 12. Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program’s risk assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof) NOTE: This criterion applies only to volunteers 20 years of age and older. 13. History of intravenous drug abuse. 14. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. 15. Known allergy to egg or aminoglycoside (gentamicin). 16. History of anaphylaxis or severe allergic reaction. 17. Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior or after study vaccination. 18. Having received any vaccinations or planned vaccinations with a killed vaccine within14 days prior or after study vaccination. 19. Chronic administration (defined as more than 14 days) of systemic immuno-suppressant drugs during a period starting from six months prior to administration of the vaccine and ending at study conclusion. (Corticosteroid nasal sprays are permissible. Persons who have used topical and inhaled steroids can be enrolled after their therapy is completed). 20. Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy. 21. Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to administration of the vaccine and ending at study conclusion. 22. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of the study vaccine, or planned administration of such a drug during the study period. 23. Study personnel.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary immunogenicity variable: MVA -specific seroconversion rate derived from the ELISA specific antibody titers 2 weeks after the last vaccination (Group 1-3: Visit 4, Group 4: Visit 2). Seroconversion is defined as the appearance of antibody titers ≥ 1:50 in a vaccinia specific IgG ELISA for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the ELISA.
Priamary safety variable: Occurrence, relationship and intensity of any specific or unspecific ECG change at any time during the study.
Occurrence, relationship and intensity of any other cardiac symptom at any time during the study.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity of the IMP |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trials ends for each individual subject with an examination at a follow-up visit 182-210 days after the last vaccination. The end of the entire trial is defined as the last subject having performed this last follow-up visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 12 |